• Gelteq secured strategic debt financing of up to USD 3.5 million to fund commercialization, expand clinical trial activity, support revenue growth.
• USD 1 million to be funded at closing; additional USD 2.5 million contingent on shareholder approval targeted for June 2026.
• Financing includes no repayments for at least six months from closing, extending near-term liquidity runway during commercialization push.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gelteq Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120800PRIMZONEFULLFEED9718135) on May 12, 2026, and is solely responsible for the information contained therein.